The CNS Market Outlook To 2012

Content

• Executive Summary
  • Patient potential
  • Global market analysis
  • Pipeline analysis
  • Competitive landscape
• Chapter 1 Epidemiology of CNS disorders
  • Summary
  • Introduction
  • Alzheimer's disease
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
  • Major depressive disorder (MDD)
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
  • Schizophrenia
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
  • Migraine
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
  • Epilepsy
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
  • Parkinson's disease
  • Overview
  • Diagnosis, treatment and management
  • Epidemiology
  • Forecast epidemiology
• Chapter 2 Global market analysis
  • Summary
  • Introduction
  • Market analysis by country
  • Licensing/generics trends
  • Market analysis by indication
  • Leading brands dynamics
  • Key events in the CNS disorders market,
  • Revised suicidal warning labeling for SSRI anti depressants
  • Increased risk of bone fractures associated with the use of SSRIs
  • Launch of Lyrica (pregabalin) as a replacement product for Pfizer's
  • Neurontin (gabapentin)
  • US FDA calls for voluntary withdrawal of all pergolide-based products
  • Launch for first transdermal patch formulation of Novartis' Exelon for the
  • treatment of AD
  • Arrival of generic competition to key products in the CNS market in 2005-6
  • Depression
  • Market analysis by drug class
  • Competitive dynamics of anti-depressants
  • Leading brands in the Anti-depressants market
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Market dynamics
  • Key brands analysis
  • Selective Norepinephrine Reuptake Inhibitors (SNRIs)
  • Key brands analysis
  • Others
  • Anti-depressants sales forecasts to 2012
  • Alzheimer's disease
  • Market analysis by drug class
  • Competitive dynamics of subclasses of anti-Alzheimer's disease
  • Leading brands in the Anti-Alzheimer's market
  • Cholinesterase inhibitors market analysis
  • Market dynamics
  • Key brands analysis
  • NMDA receptor antagonists
  • Market dynamics
  • Key brands analysis
  • Anti-Alzheimer's drugs sales forecasts to 2012
  • Epilepsy
  • Market analysis by drug class
  • Competitive dynamics of subclasses of anti-epileptics
  • Leading brands in the anti-epileptic market
  • Traditional anti-epileptics
  • Market dynamics
  • Key brands analysis
  • Second generation anti-epileptics market analysis
  • Market dynamics
  • Key brands analysis
  • Anti-epiletics sales forecasts to 2012
  • Migraine
  • Market analysis by drug class
  • Leading brands of anti migraine drugs
  • Triptans
  • Key brands analysis
  • Anti-migraine sales forecasts to 2012
  • Parkinson's disease
  • Market analysis
  • Leading brands in the anti Parkinson's market Table 2.30 summarizes the
  • performance of the leading anti-Parkinson's disease brands in 2005-6
  • COMT inhibitors
  • Key brands analysis
  • Dopaminergics
  • Key brands analysis
  • Dopamine Agonists
  • Key brands analysis
  • Anti-Parkinson's drugs sales forecasts to 2012
  • Schizophrenia
  • Market analysis
  • Leading brands in the Schizophrenia market
  • Typical anti-psychotics
  • Atypical antipsychotics
  • Key brands analysis
  • Schizophrenia drugs sales forecasts to 2012
  • Total CNS disorders' sales forecasts to 2012
• Chapter 3 Pipeline analysis
  • Summary
  • Introduction
  • Key trends in R&D
  • New class of drugs
  • Dual mechanism of action
  • Combination drugs
  • New drug delivery formulations
  • The CNS disorders pipeline
  • Leading drugs in development
  • Profiles of key pipeline products
  • Phase II compounds
  • Ketasyn/AC-1202
  • PBT2 (Metal Protein Attenuating Compound)
  • Phase III compounds
  • vilazodone
  • ACP 103 (pimavanserin)
  • MK-0974
  • safinamide
  • Drugs in registration
  • DVS-233 (desvenlafaxine)
  • Trexima (sumatriptan/naproxen)
  • Vimpat (lacosamide)
  • Recently marketed drugs
  • Invega (paliperidone)
  • Neupro (rotigotine transdermal patch)
  • Inovelon (rufinamide)
  • Pipeline forecasts
  • CNS disorders pipeline forecasts
• Chapter 4 Competitive landscape
  • Summary
  • Introduction
  • Company market shares
  • Johnson & Johnson
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Glaxo SmithKline
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Pfizer
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Lilly
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Sanofi Aventis
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Novartis
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • AstraZeneca
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Wyeth
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
  • Forest Labs
  • Overview
  • Sales focus by indication
  • Marketed product portfolio
  • R&D pipeline analysis
  • Sales and Promotion analysis
  • Drivers of growth
  • Resistors of growth
• Chapter 5 Appendix
  • IMS data
  • N1 Anaesthetics - Includes Anaesthetics local, others
  • N2 Analgesics
  • Index
• List of Figures
  • Figure 1.1: Typical treatment patterns in the treatment of Alzheimer's disease
  • Figure 1.2: Typical treatment patterns in the treatment of MDD
  • Figure 1.3: Typical treatment patterns in the treatment of schizophrenia
  • Figure 1.4: Typical treatment patterns in the treatment of PD
  • Figure 2.5: Global CNS market share by geography, 2006
  • Figure 2.6: Sales of types of CNS disorder brands, 2005-06
  • Figure 2.7: Competitive dynamics of the global CNS market by indication, 2006
  • Figure 2.8: Competitive dynamics of the leading 10 brands in the global CNS market, 2006
  • Figure 2.9: Competitive dynamics of the global anti-depressant market, 2005-6
  • Figure 2.10: Competitive dynamics of the global AD market, 2005-6
  • Figure 2.11: Competitive dynamics of the global AED market, 2005-6
  • Figure 2.12: Competitive dynamics of the global schizophrenia market, 2005-6
  • Figure 3.13: Prevailing R&D approaches, 2006
  • Figure 3.14: The CNS pipeline by indication and stage of development, 2006
  • Figure 3.15: Leading recently launched products and late-stage R&D compounds indicated for the treatment of CNS disorders, 2006
  • Figure 4.16: Competitive dynamics of the leading players in the global CNS market, 2006
  • Figure 4.17: J&J's CNS portfolio sales by indication, 2006
  • Figure 4.18: GSK's CNS portfolio sales by indication, 2006
  • Figure 4.19: Pfizer's CNS portfolio sales by indication, 2006
  • Figure 4.20: Lilly's CNS portfolio sales by indication, 2006
  • Figure 4.21: Sanofi Aventis' CNS portfolio sales by indication, 2006
  • Figure 4.22: Novartis' CNS portfolio sales by indication, 2006
  • Figure 4.23: AstraZenca's CNS portfolio sales by indication, 2006
  • Figure 4.24: Wyeth's CNS portfolio sales by indication, 2006
  • Figure 4.25: Forest Labs' CNS portfolio sales by indication, 2006
• List of Tables
  • Table 1.1: Estimated prevalence of CNS disorders across the seven major pharmaceutical markets, 2006
  • Table 1.2: Estimated prevalence of Alzheimer's disease across seven major markets, 2006
  • Table 1.3: Forecast epidemiology of AD across the seven major markets, 2006-12
  • Table 1.4: Estimated prevalence of MDD across seven major markets, 2006
  • Table 1.5: Forecast epidemiology of MDD across the seven major markets, 2006-12
  • Table 1.6: Estimated prevalence of schizophrenia across seven major markets, 2006
  • Table 1.7: Forecast epidemiology of schizophrenia across seven major markets, 2006
  • Table 1.8: Estimated prevalence of migraine across seven major markets, 2006
  • Table 1.9: Forecast epidemiology of migraine across seven major markets, 2006
  • Table 1.10: Estimated prevalence of epilepsy across seven major markets, 2006
  • Table 1.11: Forecast epidemiology of epilepsy across seven major markets, 2006
  • Table 1.12: Estimated prevalence of PD across seven major markets, 2006
  • Table 1.13: Forecast epidemiology of PD across seven major markets, 2006
  • Table 2.14: Breakdown of the global CNS market by indication, 2002-06
  • Table 2.15: Leading brands in the global CNS disorders market, 2005-06
  • Table 2.16: Breakdown of the global anti-depressant market by drug class, 2002-06
  • Table 2.17: Leading anti-depressant products in the global CNS market, 2005-06
  • Table 2.18: Leading SSRI brands in the global CNS market, 2005-06
  • Table 2.19: Anti-depressants sales forecast, 2006-12
  • Table 2.20: Breakdown of the global anti-Alzheimer's market by drug class, 2002-06
  • Table 2.21: Leading AD products in the global CNS market, 2005-06
  • Table 2.22: Anti-AD products' sales forecast, 2006-12
  • Table 2.23: Breakdown of the global Epilepsy market by drug class, 2002-06
  • Table 2.24: Leading AED products in the global CNS market, 2005-06
  • Table 2.25: Anti-epileptics' sales forecast, 2006-12
  • Table 2.26: Breakdown of the global migraine market by drug class, 2002-06
  • Table 2.27: Leading anti migraine products in the global CNS market, 2005-06
  • Table 2.28: Anti-migraine products' sales forecast, 2006-12
  • Table 2.29: Breakdown of the global anti-PD market by drug class, 2002-06
  • Table 2.30: Leading brands in the global PD market, 2005-06
  • Table 2.31: Anti-PD products' sales forecast, 2006-12
  • Table 2.32: Breakdown of the global schizophrenia market by drug class, 2002-06
  • Table 2.33: Leading products in the global schizophrenia market, 2005-06
  • Table 2.34: Schizophrenia products' sales forecast, 2006-12
  • Table 2.35: CNS market sales forecasts by drug class, 2006-12
  • Table 3.36: CNS disorders pipeline forecasts, 2007-12
  • Table 4.37: Leading players in the global CNS disorders market, 2005-6
  • Table 4.38: J&J's CNS product portfolio, 2005-6
  • Table 4.39: J&J's CNS R&D product pipeline, 2006
  • Table 4.40: Promotional spends on major drugs by J&J, 2005-06
  • Table 4.41: GSK's CNS product portfolio, 2005-06
  • Table 4.42: GSK's CNS R&D product pipeline, 2006
  • Table 4.43: Promotional spends on major drugs by GSK, 2005-06
  • Table 4.44: Pfizer's CNS product portfolio, 2005-6
  • Table 4.45: Pfizer's CNS R&D product pipeline, 2006
  • Table 4.46: Promotional spends on major drugs by Pfizer, 2005-06
  • Table 4.47: Lilly's CNS product portfolio, 2005-6
  • Table 4.48: Lilly's CNS R&D product pipeline, 2006
  • Table 4.49: Promotional spends on major drugs by Lilly, 2005-06
  • Table 4.50: Sanofi Aventis' CNS product portfolio, 2005-6
  • Table 4.51: Sanofi Aventis' CNS R&D product pipeline, 2006
  • Table 4.52: Promotional spends on major drugs by Sanofi Aventis, 2005-06
  • Table 4.53: Novartis' CNS product portfolio, 2005-6
  • Table 4.54: Novartis' CNS R&D product pipeline, 2006
  • Table 4.55: Promotional spends on major CNS drugs by Novartis, 2005-06
  • Table 4.56: AstraZeneca's CNS product portfolio, 2005-6
  • Table 4.57: AstraZeneca's CNS R&D product pipeline, 2006
  • Table 4.58: Promotional spends on major CNS drugs by AstraZeneca, 2005-06
  • Table 4.59: Wyeth's CNS product portfolio, 2005-6
  • Table 4.60: Wyeth's CNS R&D product pipeline, 2006
  • Table 4.61: Promotional spends on major CNS drugs by Wyeth, 2005-06
  • Table 4.62: Forest Lab's CNS product portfolio, 2005-6
  • Table 4.63: Forest Lab's CNS R&D product pipeline, 2006
  • Table 4.64: Promotional spends on major CNS drugs by Forest, 2005-06